GSA Capital Partners’s BioCardia BCDA Stock Holding History

GSA Capital Partners’s Portfolio BCDA Stock Details BCDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,303	Closed	-$14K	–	1721
2025 Q4	$14K	Buy	+11,303	New	+$15.4K	﹤0.01%	1610

Other funds holding BCDA

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pingora Partners Wilson, Wyoming $169M AUM 56.08% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

GSA Capital Partners's BCDA Position: Q1 2026 in Review

GSA Capital Partners sold out of BioCardia (BCDA) in Q1 2026, closing a stake of 11,303 shares — an estimated $14K sold.

GSA Capital Partners first reported a position in BCDA in Q4 2025 and held it in 1 quarter. The position peaked at $14K in Q4 2025. 18 funds tracked by Wall St. Rank hold BCDA as of Q1 2026.

GSA Capital Partners reported no remaining BioCardia position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 11,303 BioCardia shares in Q1 2026, an estimated $14K.
GSA Capital Partners first reported a position in BioCardia in Q4 2025 and held it in 1 quarter.
GSA Capital Partners's BioCardia position peaked at $14K in Q4 2025.
18 funds tracked by Wall St. Rank held BioCardia as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.